TheEdgeResearch
Home / Stocks / PXMBF

Paxman AB (publ) (PXMBF)

OTC Healthcare Medical - Devices
$3.50 ▲ +0.00%
Market Cap
$81.5M
Sector
Healthcare
Industry
Medical - Devices
Beta
0.46
52-Wk Range
3.5-3.5
CEO
Richard Paxman
Country
SE
Currency
USD

Paxman AB (publ) operates in the Medical - Devices industry of the Healthcare sector, headquartered in Karlshamn, BL, SE. The stock last traded at $3.50, up 0.00% on the session, giving a market capitalisation of $81.5M. On trailing twelve-month figures it carries a trailing P/E of -96.86, a net margin of -3.2%. Its beta of 0.46 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-96.86
Price / Sales
3.14
Price / Book
2.58
EV / EBITDA
32.82
Gross margin
49.0%
Operating margin
-0.4%
Net margin
-3.2%
Return on equity
Debt / equity
0.01
Current ratio
4.54
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
144
IPO date
2019-04-23
Headquarters
Karlshamn, BL, SE
About Paxman AB (publ)

Paxman AB (publ), operating alongside its subsidiaries, specializes in engineering and marketing the Paxman scalp cooling system. This innovative solution aims to significantly mitigate hair loss experienced by patients undergoing chemotherapy, with its reach extending across a broad international presence including Europe, North America (the United States and Mexico), Asia (Japan and other areas), Oceania, and Central and South America. Its primary clientele consists of oncology clinics and healthcare institutions. The company also maintains a research and development partnership with the National University Hospital in Singapore, focused on creating a mobile cooling and compression apparatus. Founded in 1996, Paxman AB (publ) is headquartered in Karlshamn, Sweden.

Comparable companies

Paxman AB (publ) is most often compared with the following Healthcare names:

BCCOYCLLKFHOFBFIMPZYLDXHFORXOYRCELSNZZFVMTHFVTIAF
More research on PXMBF
PXMBF technical analysis PXMBF TheEdge Score Compare against peers
Open full interactive analysis & DCF →